摘要
Objective: To study the pharmacokinetics of tamoxifen at a high dosage, which will offer a theoretical support for an appropriate clinical use of the medicine in non-small cell lung cancer (NSCLC) patients. Methods: Three qualified NSCLC patients are selected and given tamoxifen (TAM) 160 mg per Os. Blood samples were collected at different times and then analyzed by high-performance liguid chromatography. The PK-GRAPH program was used to obtain the parameters. Results: The concentration-time courses of the TAM 160 mg were fitted to one-compartment model. The pharmacokinetic parameters were estimated as follows: Tmax (6.35 ± 1.24) h, Cmax (217.39 ± 7.71) ng/mL, AUC (12 127.39 ± 636.16) ng·h/mL and T 1/2ke (34.13 ± 2.97) h. Conclusion TAM 160mg one day per Os cannot reach the effective maintenance concentration in vivo required for reversing MDR in vitro. Loading-maintenance dose strategy is recommended to study the pharmacodynamics of tamoxifen at a high dosage in NSCLC patients.
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 204-207 |
| 页数 | 4 |
| 期刊 | Academic Journal of Xi'an Jiaotong University |
| 卷 | 19 |
| 期 | 2 |
| 出版状态 | 已出版 - 11月 2007 |
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
-
可持续发展目标 3 良好健康与福祉
学术指纹
探究 'Research on pharmacokinetics of high-dose tamoxifen in non-small cell lung cancer patients' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver